Impax Laboratories, Inc. (NASDAQ:IPXL)‘s stock had its “buy” rating reiterated by Deutsche Bank AG in a note issued to investors on Tuesday. They currently have a $23.00 price objective on the specialty pharmaceutical company’s stock. Deutsche Bank AG’s price target suggests a potential upside of 9.52% from the company’s current price.

Other analysts have also issued reports about the stock. Cantor Fitzgerald set a $20.00 price target on shares of Impax Laboratories and gave the stock a “buy” rating in a research report on Wednesday, August 9th. BidaskClub upgraded shares of Impax Laboratories from a “hold” rating to a “buy” rating in a research report on Wednesday, July 12th. Zacks Investment Research upgraded shares of Impax Laboratories from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a research report on Tuesday, July 11th. Citigroup Inc. raised their price target on shares of Impax Laboratories to $23.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, BMO Capital Markets restated a “hold” rating and issued a $16.00 price target on shares of Impax Laboratories in a research report on Friday, June 23rd. Four investment analysts have rated the stock with a sell rating, eleven have given a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $18.56.

Impax Laboratories (IPXL) traded down 0.95% during trading on Tuesday, reaching $20.80. 594,341 shares of the company’s stock were exchanged. The company’s market capitalization is $1.49 billion. Impax Laboratories has a 1-year low of $7.75 and a 1-year high of $27.29. The company’s 50-day moving average is $19.07 and its 200-day moving average is $15.54.

Impax Laboratories (NASDAQ:IPXL) last posted its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.04. Impax Laboratories had a negative net margin of 71.08% and a positive return on equity of 9.05%. The business had revenue of $202.08 million for the quarter, compared to analyst estimates of $195.62 million. During the same period last year, the business posted $0.21 EPS. Impax Laboratories’s revenue was up 17.1% compared to the same quarter last year. Equities research analysts expect that Impax Laboratories will post $0.70 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/09/19/impax-laboratories-ipxl-buy-rating-reiterated-at-deutsche-bank-ag.html.

Several large investors have recently modified their holdings of the company. Maverick Capital Ltd. grew its position in shares of Impax Laboratories by 6,705.5% during the 2nd quarter. Maverick Capital Ltd. now owns 7,159,336 shares of the specialty pharmaceutical company’s stock worth $115,265,000 after buying an additional 7,054,136 shares during the period. Vanguard Group Inc. grew its position in shares of Impax Laboratories by 9.1% during the 2nd quarter. Vanguard Group Inc. now owns 6,821,118 shares of the specialty pharmaceutical company’s stock worth $109,820,000 after buying an additional 569,723 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Impax Laboratories by 23.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,244,580 shares of the specialty pharmaceutical company’s stock worth $52,238,000 after buying an additional 607,503 shares during the period. North Tide Capital LLC grew its position in shares of Impax Laboratories by 50.0% during the 1st quarter. North Tide Capital LLC now owns 3,000,000 shares of the specialty pharmaceutical company’s stock worth $37,950,000 after buying an additional 1,000,000 shares during the period. Finally, Frontier Capital Management Co. LLC grew its position in shares of Impax Laboratories by 43.2% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 1,585,828 shares of the specialty pharmaceutical company’s stock worth $25,532,000 after buying an additional 478,168 shares during the period. Institutional investors own 86.26% of the company’s stock.

Impax Laboratories Company Profile

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Analyst Recommendations for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.